Saracatinib

Saracatinib is a dual inhibitor of the tyrosine kinases c-Src and Abl (IC50 = 2.7 and 30 nM, respectively). It less effectively inhibits other receptor and non-receptor tyrosine kinases as well as assorted serine/threonine kinases. Saracatinib is orally available and blocks cell motility, migration, adhesion, invasion, proliferation, differentiation, and survival. Through its effects on c-Src, it reduces osteoclast bone resorption. Saracatinib also blocks denque virus RNA replication through its effect on Fyn kinase.Formal Name: N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methyl-1-piperazinyl)ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-4-quinazolinamine. CAS Number: 379231-04-6. Synonyms: AZD 0530. Molecular Formula: C27H32ClN5O5. Formula Weight: 542.0. Purity: >90%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 10 mg/ml, DMSO: 10 mg/ml, DMSO:PBS (pH 7.2) (1:1): 0.5 mg/ml, Ethanol: 0.1 mg/ml. lambdamax: 236, 259 nm. SMILES: ClC1=CC=C2C(OCO2)=C1NC3=NC=NC4=C3C(OC5CCOCC5)=CC(OCCN6CCN(C)CC6)=C4. InChi Code: InChI=1S/C27H32ClN5O5/c1-32-6-8-33(9-7-32)10-13-35-19-14-21-24(23(15-19)38-18-4-11-34-12-5-18)27(30-16-29-21)31-25-20(28)2-3-22-26(25)37-17-36-22/h2-3,14-16,18H,4-13,17H2,1H3,(H,29,30,31). InChi Key: OUKYUETWWIPKQR-UHFFFAOYSA-N.